New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
08:05 EDTXNCRXencor appoints John Desjarlais as Chief Scientific Officer
Xencor announced the appointment of John R. Desjarlais to senior vice president of research and chief scientific officer. Desjarlais joined Xencor in 2001 and was promoted to vice president of research in 2006, where he oversees all aspects of discovery and research at the company including technology development, protein and antibody engineering and generation of drug candidates.
News For XNCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
07:23 EDTXNCRXencor reports top-line XmAb5871 Phase 1b/2a results
Subscribe for More Information
07:22 EDTXNCRXencor reports XmAb7195 top-line interim Phase 1a results
Xencor reported top-line interim results from a Phase 1a study for XmAb7195. The data show rapid reduction of circulating free IgE levels to below the limit of detection in 90% of XmAb7195 treated subjects that had detectable free IgE pre-dose, including those at the lowest dose evaluated of 0.3 mg/kg. Total IgE levels were also reduced in a parallel fashion. A dose limiting toxicity of transient, asymptomatic thrombocytopenia was observed at the 3.0 mg/kg dose. Two subjects with high pre-dose IgE levels were treated with XmAb7195, one each at 0.75 mg/kg and 3.0 mg/kg doses, and both had reduction of free IgE levels to below the limit of detection lasting for at least one week. XmAb7195 is an anti-IgE monoclonal antibody containing Xencor's proprietary XmAb Immune Inhibitor Fc domain that targets FcăRIIb, which results in rapid clearance of free and total IgE and inhibition of the function of IgE expressing B cells.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use